Life-course blood pressure in relation to brain volumes by Power, Melinda C. et al.
Life-course blood pressure in relation to brain volumes
Melinda C. Power, ScDa,l, Andrea L. C. Schneider, MDa,c, Lisa Wruck, PhDd, Michael 
Griswold, PhDe, Laura H. Coker, PhDg,h, Alvaro Alonso, MDi, Clifford R. Jack Jr., MDj, David 
Knopman, MDk, Thomas H. Mosley, PhDf, and Rebecca F Gottesman, MDa,b
aDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North 
Wolfe Street, Baltimore, MD, 21205
bDepartment of Neurology, Johns Hopkins University School of Medicine, 733 N Broadway, 
Baltimore, MD, 21205
cDepartment of Medicine, Johns Hopkins University School of Medicine, 733 N Broadway, 
Baltimore, MD, 21205
dDepartment of Biostatistics, University of North Carolina Gillings School of Public Health, 135 
Dauer Drive, Chapel Hill, NC, 27599
eCenter of Biostatistics and Bioinformatics, University of Mississippi Medical Center, 2500 North 
State Street, Jackson, MS, 39216
fDepartment of Medicine, University of Mississippi Medical Center, 2500 North State Street, 
Jackson, MS, 39216
gDepartment of Neurology, Wake Forest School of Medicine, 1 Medical Center Boulevard, 
Winston-Salem, NC, 27157
hDepartment of Social Science & Health Policy, Wake Forest School of Medicine, 1 Medical 
Center Boulevard, Winston-Salem, NC, 27157
iDivision of Epidemiology and Community Health, School of Public Health, University of 
Minnesota, 1300 S 2nd St, Minneapolis, MN 55454
jDepartment of Radiology, Mayo Clinic, 200 First Street, Rochester, MN, 55905
kDepartment of Neurology, Mayo Clinic, 200 First Street, Rochester, MN, 55905
lDepartment of Epidemiology and Biostatistics, George Washington University Milken Institute 
School of Public Health, Washington, DC, 20052
Abstract
Corresponding Author: Melinda C. Power, Department of Epidemiology and Biostatistics, George Washington University Milken 
Institute School of Public Health, 950 New Hampshire Avenue NW, 5th Floor, Washington DC 200052, melindacpower@gmail.com 
T: 202.994.7778 F: 202.994.0082. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONFLICTS OF INTEREST
Drs. Schneider, Wruck, Griswold, Coker, Alonso, Power, Deal, Sharrett, Mosley, and Gottesman report no conflicts of interest.
HHS Public Access
Author manuscript
Alzheimers Dement. Author manuscript; available in PMC 2017 August 01.
Published in final edited form as:













INTRODUCTION—The impact of blood pressure on brain volumes may be time- or pattern-
dependent.
METHODS—In 1678 participants from the Atherosclerosis Risk in Communities Neurocognitive 
Study, we quantified the association between measures and patterns of blood pressure over three 
time points (~24 or ~15 years prior and concurrent with neuroimaging) with late life brain 
volumes.
RESULTS—Higher diastolic blood pressure ~24 years prior, higher systolic and pulse pressure 
~15 years prior, and consistently elevated or rising systolic blood pressure from ~15 years prior to 
concurrent with neuroimaging, but not blood pressures measured concurrent with neuroimaging, 
were associated with smaller volumes. The pattern of hypertension ~15 years prior and 
hypotension concurrent with neuroimaging was associated with smaller volumes in regions 
preferentially affected by Alzheimer’s disease (e.g., hippocampus: −0.27 standard units, 95%CI:
−0.51,−0.03).
DISCUSSION—Hypertension 15 to 24 years prior is relevant to current brain volumes. 
Hypertension followed by hypotension appears particularly detrimental.
Keywords
magnetic resonance imaging; brain volumes; neurodegeneration; Alzheimer’s disease; 
hypertension; blood pressure; hypotension; epidemiology; cohort study; human
1. INTRODUCTION
Elevated blood pressure in midlife appears to confer excess risk of cognitive impairment [8, 
9] while associations with elevated late life blood pressure are typically null or protective.[8, 
10] This finding appears attributable, at least in part, to differences in the timing or duration 
of elevated blood pressure relative to cognitive assessment.[11] Additionally, the pattern of 
blood pressure over the life-course may be more informative than blood pressure at any 
single time point.[6, 11] As declining brain volume due to neurodegeneration occurs in 
dementia and may precede clinically noticeable change in cognition,[12–14] understanding 
how life-course blood pressure is related to brain volumes may provide mechanistic insights 
and has implications for treatment decisions. Our objective was to evaluate the relation 
between life-course blood pressure, including patterns of blood pressure, with brain volumes 




The Atherosclerosis Risk in Communities (ARIC) study recruited persons ages 45 to 65 in 
1987–1989 from four United States communities: Minneapolis suburbs, Minnesota; Forsyth 
County, North Carolina; Washington County, Maryland; and Jackson, Mississippi. We 
consider information on blood pressure from three study visits spaced at intervals of 
approximately a decade: Visit 1, 1987–1989; Visit 4, 1996–1998; and Visit 5, 2011–2013. 
(We do not consider blood pressure data from Visit 2 (1990–1992) or Visit 3 (1993–1995) to 
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limit the number of comparisons.) A sample of Visit 5 participants lacking contraindications 
for MRI, all of whom were over age 65, were invited to complete brain MRI at Visit 5 as 
part of ARIC-NCS. In accordance with the pre-specified sampling strategy, all Visit 5 
participants with evidence of cognitive impairment or a previous ARIC study brain MRI and 
a stratified random sample of the remaining participants, with strata based on age and study 
site, were invited to complete MRI. In addition to excluding persons without relevant MRI 
data or complete blood pressure and covariate data, we excluded persons with multiple 
sclerosis, brain tumor, surgery/radiation to the head, or confirmed stroke (n=82), participants 
who were not black or white (n=6), and black participants from Minnesota or Maryland 
(n=9). This study was approved by the institutional review boards of all participating 
institutions. All subjects provided written informed consent to participate at each study visit.
2.2 BLOOD PRESSURE
At each visit, study personnel measured systolic and diastolic blood pressure (SBP and 
DBP) up to three times according to a standardized protocol; we used the mean of the two 
final measurements. Antihypertensive medication use was determined through visual 
inspection of medications and linkage to Medi-Span Therapeutic Classification codes.
We considered those with SBP≥140 mmHg or DBP≥90 mmHg, antihypertensive medication 
use, or self-report of physician diagnosed hypertension at the current or any past study visit 
as having a “history of hypertension.” In addition to considering measured SBP, DBP, and 
pulse pressure (PP, defined as SBP minus DBP) as continuous variables, we also classified 
persons as hypotensive (SBP<90 mmHg or DBP<60 mmHg), hypertensive (≥140 mmHg 
SBP or ≥90 mmHg DBP in the absence of hypotension), or normotensive (the absence of 
hyper- or hypotension) at each study visit.
We further derived summaries of blood pressure patterns, including within-person change in 
SBP, DBP and PP across pairs of study visits (Visit 1 to 5, Visit 1 to 4, Visit 4 to 5) and a 
six-category variable describing the pattern of measured blood pressure across each pair of 
visits (hypotensive or normotensive/hypertensive at the earlier visit by hypotensive/
normotensive/hypertensive at the later visit).
2.3 BRAIN VOLUMES
3T brain MRIs were completed following identical protocols at each study center. Each 
center underwent a qualifying process and phantom scans were completed bi-monthly and 
after upgrades. All scans included a sagittal T1-weighted 3D volumetric Magnetization 
Prepared Gradient Echo (MPRAGE) pulse sequence, allowing quantification of brain 
volumes. The ARIC MRI Reading Center used Freesurfer (version 5.1) to measure grey 
matter volumes. We report on associations with total brain volume, lobar grey matter 
volumes (frontal, parietal, temporal, occipital), total volume of the deep grey structures 
(insula, thalamus, caudate, putamen, and pallidum), total combined volume of the 
parahippocampal, entorhinal, and inferior parietal lobules, hippocampus, precuneus, and 
cuneus (denoted as the Alzheimer’s Disease (AD) signature region)[15] and hippocampal 
volume.
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We used data obtained at Visits 1, 4, and 5/ARIC-NCS to define covariates. We calculated 
body mass index (BMI) as measured weight (kg) divided by the square of measured height 
(m) and mean arterial pressure (MAP) as 2/3 DBP + 1/3 SBP. We defined 
hypercholesterolemia as measured total cholesterol of >200 mg/dL and diabetes as self-
reported diagnosis, ≥126 mg/dL fasting glucose, ≥200 mg/dL non-fasting glucose, or use of 
diabetes medications. The ARIC MRI Reading Center used in-house algorithms to estimate 
total brain and intracranial volume.[16] We defined all other covariates based on information 
recorded about the study visit alone or in combination with information provided via self-
report.
2.5 STATISTICAL ANALYSES
We used separate weighted linear regression models to quantify the association between 
each of our blood pressure and z-scored MRI brain volume measures. Sampling weights 
were used to account for the stratified random sampling approach used to select Visit 5 
participants for MRI; thus we estimate the association in the Visit 5 ARIC participant 
population. All analyses were adjusted for potential confounders, including both time-
invariant confounders --gender, education (<12/12–16/>16 years), race/center (black in 
Jackson/black in Forsyth County/white in Forsyth County/white in Minneapolis/white in 
Washington County), estimated total intracranial volume and its interaction with gender -- 
and confounders that vary over time --body mass index (BMI, <25/25 to <30/≥30 kg/m2), 
diabetes, smoking status (current/former/never), hypercholesterolemia, and (excluding 
analyses considering history of hypertension) antihypertensive medication use. Time-varying 
confounders were assessed at the appropriate study visit for analyses of visit-specific blood 
pressure (e.g., Visit 4 values if considering Visit 4 SBP). For analyses of patterns of blood 
pressure, exploratory analyses provided no support for the presence of time-varying 
confounding[17]; therefore, we adjusted for time-varying confounders by adjusting for 
status at multiple time points (e.g., both Visit 1 and Visit 5 smoking status if considering 
change in SBP from Visit 1 to 5). Analyses of within-person change in blood pressure were 
additionally adjusted for starting blood pressure. To isolate the impact of PP, given that 
higher blood pressure is associated with greater PP, analyses of PP were additionally 
adjusted for MAP, and analyses of change in PP were adjusted for change in MAP. All 
continuous explanatory variables were modeled using linear terms. We did not correct for 
multiple comparisons in these primary analyses because the association of blood pressure 
with one imaging feature is likely correlated with other imaging features.
We conducted multiple sensitivity analyses. To evaluate sensitivity to our exclusion criteria, 
we repeated our analyses (a) allowing participants with less than complete blood pressure 
data to contribute data, and (b) including persons with stroke. We also repeated our analyses 
omitting use of sampling weights to understand the influence of the sampling strategy. 
Finally, we derived and applied inverse probability of attrition weights (IPAW)[11, 18, 19] to 
address potential selection bias due to attrition from ARIC Visit 1 to Visit 5 (see 
Supplemental Methods). In combination with the sampling weights, the IPAW weighted 
estimates are designed to recover the association that would have been observed under either 
(i) no loss-to-follow-up (i.e. full follow-up for all living participants) or (ii) attrition that is 
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statistically independent of blood pressure (i.e., full follow-up for all living participants and 
a random mechanism accounting for who dies), under the assumptions that death and drop-
out are missing at random conditional on observed data and that the weights models are 
correctly specified.
We considered effect modification by race, age, and gender for all analyses and by 
antihypertensive medication use (overall, and by class of medication – angiotension-
converting enzyme inhibitors/angiotension II receptor blockers, beta blockers, calcium 
channel blockers, and diuretics, when the prevalence of use was >5%) for analyses of visit-
specific measured blood pressure using multiplicative interaction terms. We evaluated 
support for effect modification using Benjamini-Hochberg corrected p-values,[20] allowing 
a false discovery rate of 5%. Throughout we consider p<0.05 to be significant and p<0.10 to 
be marginally significant and report 95% confidence intervals. All analyses were completed 
using SAS, Version 9.3 or R, Version 3.0.1.
3. RESULTS
The study sample included up to 1687 participants. The weighted sample population was 
predominately female (61%) and well-educated (11% with less than a high school diploma 
or equivalent certification, 48% with a college degree); 31% were white from Minneapolis, 
28% were white from Washington County, 21% were white and 1% were black from Forsyth 
County, and 19% were black from Jackson. Table 1 details additional sample characteristics 
while blood pressure patterns are described in Table 2 (unweighted versions of Tables 1 and 
2 are provided as appendix Tables A.1 and A.2).
3.1 HISTORY OF HYPERTENSION
A history of hypertension at any study visit was related to smaller parietal and frontal lobe 
cortical volumes in late life (Figure 1; appendix Table A.3). A history of hypertension at 
either Visit 1 or Visit 5, but not Visit 4, was associated with smaller temporal lobe and AD 
signature region volumes (total combined volume of the parahippocampal, entorhinal, and 
inferior parietal lobules, hippocampus, precuneus, and cuneus). A history of hypertension at 
Visit 5, concurrent with neuroimaging, appeared associated with smaller total brain volumes, 
while a history of hypertension at Visit 1, ~24 years prior, was marginally associated with 
smaller hippocampal volumes.
3.2 MEASURED BLOOD PRESSURE
3.2.1 Blood Pressure ~24 Years Prior to Neuroimaging (Visit 1)—Higher SBP at 
Visit 1, ~24 years prior to neuroimaging, was significantly associated with smaller parietal 
lobe volumes and marginally associated with smaller AD signature region volumes, but was 
not associated with other late life volumes (Figure 1; appendix Table A.4). Higher DBP at 
Visit 1 was significantly or marginally associated with smaller volumes in late life for all 
regions except the deep grey matter and hippocampus. Greater Visit 1 PP was associated 
with larger frontal, occipital, and temporal lobe cortical volumes.
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3.2.2 Blood Pressure ~15 Years Prior to Neuroimaging (Visit 4)—Higher SBP at 
Visit 4, ~15 years prior to neuroimaging, was significantly or marginally associated with 
smaller brain volumes in almost all regions; there was no association with hippocampal 
volume and higher Visit 4 SBP was marginally associated with larger deep grey matter 
volumes (Figure 1; appendix Table A.4). Higher DBP at Visit 4 was associated with smaller 
AD signature region and temporal, parietal, and occipital lobe cortical volumes. Visit 4 PP 
was not associated with volumes.
3.2.3 Blood Pressure Concurrent with Neuroimaging (Visit 5)—There was little 
support for an association between measures of blood pressure at the time of neuroimaging 
(Visit 5) and late life brain volumes, with a few exceptions (Figure 1; appendix Table A.4).
3.3 HYPERTENSION AND HYPOTENSION
Associations between categories of measured blood pressure and brain volumes were 
generally consistent with expectations given the findings considering SBP and DBP 
separately (Figure 1, appendix Table A.5). At Visit 1, ~24 years prior to neuroimaging, 
hypotension was associated with larger late life total brain volumes and parietal lobe cortical 
volumes, while hypertension was marginally associated with smaller hippocampal volumes. 
At Visit 4, ~15 years prior to neuroimaging, hypotension was associated with larger parietal 
lobe and AD signature region volumes as well as smaller deep grey volumes, while 
hypertension was associated with smaller total brain, temporal lobe, AD signature region, 
and hippocampal volumes. With the exception of an association between concurrent 
hypertension and smaller frontal lobe volumes, categories of blood pressure assessed 
concurrent with neuroimaging (Visit 5) were not associated with brain volumes.
3.4 WITHIN-PERSON CHANGE IN BLOOD PRESSURE
Higher SBP at Visit 4 relative to Visit 1 (i.e., at ~15 years prior relative to ~24 years prior to 
neuroimaging) was significantly associated with smaller total brain, AD signature region, 
and temporal, parietal, and occipital lobe cortical volumes (Figure 2; appendix Table A.6). 
Positive within-person change in DBP from Visit 1 to Visit 4 was associated with smaller 
temporal lobe and AD signature region volumes. Change in PP from Visit 1 to Visit 4 was 
not associated with volumes. Change in blood pressure from Visit 1 or Visit 4 to the time of 
neuroimaging (Visit 5) was not associated with volumes, with a few exceptions (Figure 2; 
appendix Table A.6).
3.5 PATTERNS OF MEASURED BLOOD PRESSURE OVER TIME
3.5.1 Categorical Patterns from ~24 to ~15 Years Prior to Neuroimaging (Visit 1 
to 4)—Persons who were hypertensive at both Visit 1 and Visit 4 (~24 and ~15 years prior 
to neuroimaging) or newly hypertensive at Visit 4 (~15 years prior to neuroimaging) 
exhibited significantly or marginally smaller late life temporal lobe, AD signature region, 
and hippocampal volumes compared to those with “normal” blood pressure throughout 
(Figure 3a; appendix Table A.7). Being hypertensive at both time points was also 
significantly associated with smaller deep grey volumes, while being newly hypertensive 
was marginally associated with larger deep grey volumes. Being newly hypertensive at Visit 
4 was also significantly associated with smaller total brain volumes. The pattern of Visit 1 
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normo- or hypotension with Visit 4 hypotension was significantly associated with greater 
parietal lobe and AD signature region volumes but smaller deep grey volumes.
3.5.2 Categorical Patterns from ~15 Years Prior to Concurrent with 
Neuroimaging (Visit 4 to 5)—Hypertension ~15 years prior to neuroimaging (Visit 4) 
followed by hypotension at the time of neuroimaging (Visit 5) was strongly associated with 
smaller temporal lobe, AD signature region, and hippocampal volumes compared to those 
with “normal” blood pressure throughout (Figure 3b; appendix Table A.7). Participants who 
were hypertensive at both Visit 4 and Visit 5 also had smaller temporal and frontal lobe 
volumes. There was marginal support for smaller total brain volumes in participants who 
were hypertensive at Visit 4 but normotensive at Visit 5.
3.5.3 Categorical Patterns from ~24 Years Prior to Concurrent with 
Neuroimaging (Visit 1 to 5)—There was no evidence to support a difference in late life 
volumes among those with alternate patterns of blood pressure status from Visit 1 to 5 those 
with “normal” blood pressure throughout, with two exceptions: a significant association 
between normo- or hypotension at Visit 1, ~24 years prior to neuroimaging, followed by 
hypertension at Visit 5, concurrent with neuroimaging, and smaller frontal lobe volumes and 
a marginally significant association between hypertension at Visit 1 with normotension at 
Visit 5 and smaller deep grey volumes (appendix Table A.7).
3.6 SENSITIVITY ANALYSES AND EFFECT MODIFICATION
All sensitivity analyses were consistent with primary analyses. There was no support for 
effect modification by any considered characteristic (all corrected p-values >0.05).
4. DISCUSSION
In our study, blood pressure status 15 to 24 years prior appears most relevant to current 
amount of brain atrophy. Specifically, diastolic hypotension ~24 years prior to neuroimaging 
appeared associated with larger late life brain volumes, while elevated blood pressure ~15 
years prior, particularly higher SBP, appeared associated with smaller late life volumes.
Our analyses of patterns of blood pressure suggested that controlling SBP may preserve 
brain volumes one to two decades later, as rising SBP and being hypertensive from ~24 
years prior to ~15 years prior or being newly hypertensive ~15 years prior were associated 
with smaller late life brain volumes. Interestingly, compared to persons with normal blood 
pressure throughout, hypertension ~ 15 years earlier followed by hypotension at the time of 
neuroimaging was associated with substantially smaller volumes in regions affected early in 
Alzheimer’s disease.[21]
Strengths of this study include life-course information on blood pressure and a large sample 
with brain MRI. Our focus on measured blood pressure is also a strength, as our study 
provides insight into the effects of achieving specific blood pressure targets. However, this 
can be viewed as a limitation given that we make the assumption that antihypertensive 
treatments act only or mostly through changing blood pressure, and thus we avoid the 
complexity of quantifying the effect of treatments and ignore the fact that standard of care 
Power et al. Page 7













changed over the study period. While lack of effect modification by antihypertensive 
medication class provides reassurance that this approach is reasonable, we acknowledge that 
we have not formally tested this assumption in our data. While confounding, 
misclassification, or selection bias cannot be completely discounted, we do not believe they 
account for our non-null findings; we adjusted for relevant confounders, non-differential 
measurement error would likely bias towards the null, and sensitivity analyses addressing 
selection, which assume the data are missing at random conditional on known predictors of 
death and drop-out, were consistent with the primary analyses. Study limitations include our 
inability to consider within-individual change in brain volumes and limited power to detect 
effect modification.
Our findings extend the work of others on the association between life-course blood pressure 
and late life brain volumes through use of a comprehensive assessment of life-course blood 
pressure over an extended period and consideration of both broad and targeted brain regions. 
For example, in prior work in ARIC considering a smaller group of participants with MRI 
earlier in life, elevated SBP six years prior to MRI was associated with greater qualitative 
ratings of ventricular size; the association with concurrent SBP was similar but only 
marginally significant.[1] Conversely, concurrent hypertension was associated with greater 
qualitative ratings of sulcal size, but blood pressure six years prior to MRI was not.[1] 
Higher baseline SBP was associated with increases in ventricular and sulcal size over 
approximately 10 years of follow-up in ARIC participants with serial MRI, while higher 
DBP appeared to protect against increases in ventricular size.[2] In a subset of Rotterdam 
Study participants, persons using antihypertensive medications at both 5 years prior to and at 
the time of MRI, a proxy for longstanding hypertension, exhibited smaller hippocampal and 
amygdalar volumes compared to those without antihypertensive medication use.[3] 
Interestingly, elevated DBP five years prior to MRI was associated with smaller 
hippocampal volumes in those without antihypertensive medication use, while higher DBP 
at the time of MRI predicted greater amygdalar volumes; SBP was not associated with 
volumes.[3] In additional analyses using the Rotterdam cohort, baseline DBP, but not SBP, 
predicted faster declines in left hippocampal volume over approximately 10 years of follow-
up.[4] Several studies report an association between midlife hypertension, in the range of 
assessed approximately 22–30 years prior to neuroimaging, and smaller late life brain 
volumes.[22–24] However, in the Framingham Offspring Cohort Study, midlife hypertension 
was not associated with change in total brain volume or temporal horn volume (a surrogate 
for hippocampal volume) over a period approximately 7–13 years later.[5]
Notably, our results on patterns of blood pressure are consistent with AGES-Reykjavik 
Study findings,[6] where lower late life DBP was associated with smaller total brain and 
grey matter volumes only in persons with a history of midlife hypertension. However, our 
results differ somewhat from those of the Rotterdam Scan Study,[7] where both high and 
low concurrent DBP, elevated midlife DBP in those without antihypertensive medication 
use, and 20-year within-person declines in DBP were associated with greater cortical 
atrophy, while there was little association with any measure of SBP.
Multiple theories may explain the finding that hypotension, when preceded by hypertension 
~15 years prior, is associated with substantially smaller brain volumes in Alzheimer’s 
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disease-related regions. Longstanding hypertension can shift the cerebral autoregulatory 
curve, leading to reduced cerebral blood flow at (relatively) lower pressures[25–27]; 
therefore, hypotension, possibly induced by overly aggressive blood pressure treatment, may 
lead to periods of ischemia and associated neurodegeneration.[28] (Note, 97% of persons 
with this pattern were taking antihypertensives in late life.) Second, areas of the brain that 
are particularly vulnerable to AD pathology (especially tauopathy) may be selectively 
vulnerable to a variety of insults. Third, poor health may lead to reductions in both blood 
pressure and brain volume. (However, of persons with this pattern, only 2% had coronary 
heart failure and 8% had coronary heart disease.) Finally, atrophy (particularly of the insula) 
might lead to autonomic dysfunction and reduced blood pressure (i.e. reverse causation).[29]
In light of the findings of the Systolic Blood Pressure Intervention Trial (SPRINT)[30], 
clinicians are likely to lower blood pressure targets for many patients. While our study 
suggests this is unlikely to confer excess harm, and may ultimately confer substantial benefit 
for most individuals, our results also suggest that caution may be warranted when pursuing 
lower targets in persons with long-standing hypertension when treatment substantially 
lowers DBP. Given the short study period, as with prior trials,[31, 32] the SPRINT Memory 
and Cognition In Decreased Hypertension (SPRINT-MIND) study will only be able to 
comment on whether short-term intensive blood pressure lowering results in a common, 
immediate harm or benefit. Thus, future epidemiologic work investigating the long-term 
impact of specific patterns of life-course blood pressure, as well as the impact of life-course 
treatment, are clearly warranted.
In summary, our study highlights the potential benefit of effective screening and subsequent 
treatment for hypertension from the time of onset forward on brain health. It also supports a 
“personalized medicine” approach to blood pressure management incorporating information 
on prior blood pressure history and the potential for harm due to diastolic hypotension in the 
chronically hypertensive.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank the staff and participants of the ARIC study for their important contributions.
Melinda C. Power is supported by the NIA (T32 AG027668). The ARIC is carried out as a collaborative study 
supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, 
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C). Neurocognitive data is collected by U01 HL096812, HL096814, HL096899, HL096902, 
HL096917 with previous brain MRI examinations funded by R01-HL70825. The sponsors had no role in the design 
and conduct of the study; collection management, analysis and interpretation of the data; or preparation review, or 
approval of the manuscript.
Dr. Clifford R. Jack Jr. serves on a scientific advisory board for Eli Lilly & Company and receives research support 
from the NIH/NIA (R01-AG011378, U01-HL096917, U01-AG024904, RO1 AG041851, R01 AG37551, 
R01AG043392, U01-AG06786) and the Alexander Family Alzheimer’s Disease Research Professorship of the 
Mayo Foundation. Dr. Knopman serves as Deputy Editor for Neurology®; serves on a Data Safety Monitoring 
Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by 
TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer’s Disease Cooperative Study; and receives 
research support from the NIH.
Power et al. Page 9















ARIC Atherosclerosis Risk in Communities study
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We searched PUBMED to identify relevant studies. [1–7] Very few studies have 
considered the influence of patterns of blood pressure over time on brain volumes. [6, 7]
Interpretation
Our study provides a comprehensive picture of the association between blood pressure 
and patterns of blood pressure over the life-course on brain volumes. We found 
hypertension 15 to 24 years prior to neuroimaging to be most relevant to current brain 
volumes. Our study also suggests that the pattern of hypertension followed by 
hypotension may be particularly detrimental.
Future directions
Our study highlights the potential benefit on brain health of effective screening and 
subsequent treatment for hypertension from the time of onset forward. However, it also 
provides support for a “personalized medicine” approach to blood pressure management 
that incorporates information on prior blood pressure history and sensitivity to diastolic 
hypotension.
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Figure 1. P-value heatmap of adjusted average difference in brain volumes in late life for a given 
contrast in measured blood pressure at each study visit
Each square contains the beta coefficient, in SD units, corresponding to a given exposure-
outcome analysis. Squares containing statistically significant associations are shaded in red 
(if negative) or green (if positive), while squares containing marginally significant 
associations are shaded in orange (if negative) or light green (if positive). Unshaded squares 
denote p-values >0.10. All analyses were weighted to account for sampling and adjusted for 
gender, race-center, education, age, estimated intracranial volume, BMI, diabetes, high 
cholesterol, smoking status, and gender*estimated intracranial volume. All analyses 
exclusive of those considering history of hypertension were also adjusted for 
antihypertensive medication use and analyses of pulse pressure were additionally adjusted 
for mean arterial pressure.
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Figure 2. P-value heatmap of adjusted average difference in brain volumes in late life for a given 
within-person change in measured blood pressure across study visits
Each square contains the beta coefficient, in SD units, corresponding to a given exposure-
outcome analysis. Squares containing statistically significant associations are shaded in red 
(if negative) or green (if positive), while squares containing marginally significant 
associations are shaded in orange (if negative) or light green (if positive). Unshaded squares 
denote p-values >0.10. Analyses were weighted to account for sampling and adjusted for 
gender, race-center, education, age, estimated intracranial volume, BMI, diabetes, high 
cholesterol, smoking status, antihypertensive medication use, starting blood pressure value, 
gender*estimated intracranial volume, and (pulse pressure only) within-person change in 
mean arterial pressure.
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Figure 3. Adjusted average difference in brain volumes in late life for a given pattern of blood 
pressure
Panel A illustrates associations with patterns from Visit 1 (~24 years prior to neuroimaging) 
to Visit 4 (~15 years prior to neuroimaging) while panel B illustrates associations with 
patterns from Visit 4 (~15 years prior to neuroimaging) to Visit 5 (concurrent with 
neuroimaging). The reference category is those with earlier normo-or hypotension and later 
normotension. Analyses were weighted to account for sampling and adjusted for gender, 
race-center, education, age, estimated intracranial volume, BMI, diabetes, high cholesterol, 
smoking status, antihypertensive medication use, and gender*estimated intracranial volume.
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Table 1










Mean (25th, 75th percentile) or %
Time to MRI (years) 24 (23, 24) 15 (14, 15) 0 (0, 0)
Age (years) 52 (47, 55) 61 (56, 64) 75 (70, 79)
Body mass index
  Normal 40% 28% 28%
  Overweight 38% 40% 40%
  Obese 22% 33% 33%
Smoking status
  Current 16% 9% 5%
  Former 32% 47% 51%
  Never 52% 43% 44%
Diabetes 4% 10% 31%
Hypercholesterolemia 58% 50% 35%
Systolic blood pressure (mmHg) 115 (103, 122) 123 (111, 132) 130 (117, 140)
Diastolic blood pressure (mmHg) 72 (65, 78) 71 (64, 77) 66 (58, 72)
Pulse pressure (mmHg) 43 (35, 48) 52 (42, 59) 64 (54, 72)
History of hypertension 31% 53% 81%
Antihypertensive medication use 19% 32% 72%
  Beta blockers** 6% 8% 29%
  Calcium channel blockers** 2% 9% 22%
  ACE Inhibitors/ARBs** 2% 11% 44%
  Diuretics** 12% 14% 40%
Measured blood pressure
  Hypotensive 9% 11% 28%
  Normotensive 83% 73% 49%
  Hypertensive 8% 16% 23%
Estimated intracranial volume (cm3) -- -- 1387 (1275, 1488)
Total brain volume (cm3) -- -- 1026 (949, 1099)
Temporal lobe cortical volume (cm3) -- -- 103 (96, 111)
Parietal lobe cortical volume (cm3) -- -- 108 (99, 116)
Occipital lobe cortical volume (cm3) -- -- 41 (38, 45)
Frontal lobe cortical volume (cm3) -- -- 152 (141, 162)
Deep grey matter (cm3) -- -- 43 (40, 45)
AD signature region volume (cm3) -- -- 60 (55, 64)
Abbreviations: ACE, angiotension-converting enzyme; AD, Alzheimer’s disease; ARB, angiotension receptor blockers; ARIC-NCS 
Atherosclerosis Risk in Communities Neurocognitive Study
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*
Weighting was used to account for the sampling strategy used to select Visit 5 participants for MRI.
**
Not mutually exclusive
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Table 2
















Mean (25th, 75th percentile) or %
Within-person change in mmHg:
  Systolic blood pressure 8 (−1, 16) 7 (−7, 19) 15 (2, 27)
  Diastolic blood pressure −1 (−8, 4) −5 (−13, 2) −6 (−14, 2)
  Pulse pressure 10 (1, 16) 12 (2, 21) 21 (12, 29)
Pattern of Measured Blood Pressure
    Hypertensive to Hypotensive <1% 4% 2%
    Normo/hypotensive to Hypotensive 10% 24% 26%
    Hypertensive to Normotensive 4% 6% 3%
    Normo/hypotensive to Normotensive 70% 43% 45%
    Always Hypertensive 4% 6% 3%
    Normo/hypotensive to Hypertensive 11% 17% 20%
Abbreviations: ARIC-NCS Atherosclerosis Risk in Communities Neurocognitive Study
*
Weighting was used to account for the sampling strategy used to select Visit 5 participants for MRI.
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